Radiotherapy for Inoperable Lung Cancer

This publication has 10 references indexed in Scilit:

• Immediate versus delayed thoracic radiotherapy (TRT) in patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) and minimal symptoms: Results of an MRC/BTS randomised trial
  Lung Cancer, 2000
• Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial
  Radiotherapy and Oncology, 1999
• Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated [correction of acclerated] radiotherapy (CHART) randomized trial in non-small-cell lung cancer. CHART Steering Committee.
  Journal of Clinical Oncology, 1998
• Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
  Journal of Clinical Oncology, 1997
• Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial
  The Lancet, 1997
• Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status
  Clinical Oncology, 1996
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
  BMJ, 1995
• A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status
  British Journal of Cancer, 1992
• Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions
  British Journal of Cancer, 1991
• A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
  Journal of Clinical Oncology, 1990